Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry.

@article{McAvoy2014QuantificationOT,
  title={Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry.},
  author={Thomas McAvoy and Michael E. Lassman and Daniel S Spellman and Zhenlian Ke and Bonnie J. Howell and Oitak Wong and Lan Zhu and Michael R. Tanen and Arie Struyk and Omar F. Laterza},
  journal={Clinical chemistry},
  year={2014},
  volume={60 4},
  pages={
          683-9
        }
}
BACKGROUND Cerebrospinal fluid (CSF) tau is a common biomarker for Alzheimer disease (AD). Measurements of tau have historically been performed using immunoassays. Given the molecular diversity of tau in CSF, the selectivity of these immunoassays has often been questioned. Therefore, we aimed to develop an analytically sensitive and selective immunoaffinity liquid chromatography-tandem mass spectrometry (LC-MS/MS) (IA-MS) assay. METHODS IA-MS sample analysis involved the addition of an… 
View on PubMed
clinchem.aaccjnls.org
65 Citations
Highly Influential Citations
3
Background Citations
7
Methods Citations
9
Results Citations
5

Figures and Tables from this paper

65 Citations

Citation Type

Citation Type

Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry
TLDR
This new MRM assay, which allowed for the first time CSF tau protein quantification without immunocapture, has important potential application to follow tau metabolism in both diagnostic and therapeutic research.
Quantification of Amyloid-β in Plasma by Simple and Highly Sensitive Immunoaffinity Enrichment and LC-MS/MS Assay.
TLDR
The IA-MS assay has sufficient analytic performance for measuring endogenous Aβ40 and Aβ42 in plasma and can lead to new lines of clinical discovery related to amyloid pathology.
Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity.
TLDR
This MS-based strategy provided results complementary to those of previous ELISA or Western Blot studies of CSF tau and could be applied to tau monitoring in human CSF cohorts.
Protein Biomarker Quantification by Immunoaffinity Liquid Chromatography-Tandem Mass Spectrometry: Current State and Future Vision.
TLDR
The purpose of this report is to provide an overview of the principles of IA-MS and to demonstrate the unique power and potential of this technology, by combining target immunoaffinity enrichment with the use of stable isotope-labeled internal standards and MS detection.
Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.
TLDR
An innovative two-step pre-fractionation strategy and a sensitive multiplex peptide detection capability using targeted high-resolution MS to quantify Tau-specific peptides covering its entire sequence provide important information on Tau biology for future therapeutic interventions, and improved molecular diagnosis of tauopathies.
Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates.
TLDR
Use of the TMTcalibratortrademark workflow dramatically improved the ability to detect tau-derived peptides that are directly related to human AD pathology, and further validation of regulated tau peptides as early biomarkers of AD is warranted and is currently being undertaken.
Simultaneous Detection of Six Isoforms of Tau Protein in Human Cerebrospinal Fluid by Multidimensional Mass Spectrometry-Based Targeted Proteomics.
TLDR
This multidimensional mass spectrometry-based targeted proteomics assay was validated and applied to simultaneous quantitative analysis of six Tau isoforms in CSF of AD patients, finding each isoform of Tau protein can be individually detected and quantified.
An immuno-enrichment free, validated quantification of tau protein in human CSF by LC-MS/MS
TLDR
A method that quantifies extracellular tau protein concentrations human cerebrospinal fluid (CSF) without antibody-based enrichment strategies and is a translational bioanalytical tool for assaying target is developed.
Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in CSF by Mass Spectrometry Provides New Biomarker Candidates
TLDR
An innovative mass spectrometry workflow is applied to enrich and enhance the detection of phosphoproteome components of AD brain tissue in CSF, and enable the quantitation of these analytes, which dramatically improved the ability to detect tau-derived peptides that are directly related to human AD pathology.
Simultaneous quantification of Myelin Basic Protein and Tau proteins in cerebrospinal fluid and serum of Multiple Sclerosis patients using nanoimmunosensor.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 25 REFERENCES
Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.
TLDR
There is a need for harmonization of CSF AD biomarker assays that can reliably, across centers, quantitate CSF biomarkers with high analytical precision, selectivity and stability over long time periods.
Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers
TLDR
The current status of LC/MS/MS using selected reaction monitoring for protein quantification is reviewed, and the use of a single antibody to achieve superior enrichment of either the protein target or the released tryptic peptide is considered.
A rapid method for cross-species quantitation of apolipoproteins A1, B48 and B100 in plasma by ultra-performance liquid chromatography/tandem mass spectrometry.
TLDR
This assay is capable of supporting cardiovascular research by providing a single assay to measure critical biomarkers across multiple species without the need for antibodies, and does so in a high-throughput manner.
Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers.
TLDR
Measurements of CSF Aβ(1-42), t-τ, and p-τ(181) with analytically qualified immunoassays reliably reflect the neuropathologic hallmarks of AD in patients at the early predementia stage of the disease and even in presymptomatic patients.
Comparison of standard- and nano-flow liquid chromatography platforms for MRM-based quantitation of putative plasma biomarker proteins
TLDR
The standard-flow platform had superior performance metrics for most peptides, and is a good choice if sufficient sample is available, compared with the nano-flow system, which was found to have an overall lower sensitivity.
Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC-MS/MS.
TLDR
The use of antipeptide antibodies to immunoenrich peptides of interest can improve the sensitivity of the approach, greatly simplify the matrix enabling shortened chromatographic runs, and facilitate the multiplexed quantification of analytes, which could reduce the costs of quantitative protein measurements in complex specimens.
Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins*
TLDR
Peptide MRM measurements in plasma digests thus provide a rapid and specific assay platform for biomarker validation, one that can be extended to lower abundance proteins by enrichment of specific target peptides (stable isotope standards and capture by anti-peptide antibodies (SISCAPA)).
MRM‐based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma
TLDR
The assay presented in this study is easy to use, robust, sensitive, and has high‐throughput capabilities through short analysis time and complete automated sample preparation, therefore well suited for CVD biomarker validation and discovery in plasma.
Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry.
TLDR
The results demonstrated significant advantages with the use of a microfluidic device technology for studying apo(a) kinetics, including enhanced sensitivity relative to conventional micro-flow chromatography, a virtually drift-free elution profile, and a stable and robust electrospray.
CSF Biomarkers for Amyloid and Tau Pathology in Alzheimer's Disease
TLDR
Identifying additional CSF components, reflecting not only the lesions characteristic to AD (plaques and tangles) but also more functional and structural brain parameters, may provide a wider profile of the changes taking place in AD brains, and be further used as reliable CSF biomarkers for AD monitoring.
...
1
2
3
...